4β-Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin

British Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2009, Pages 38-43

  Diczfalusy, Ulf ^a   Kanebratt, Kajsa P ^a,b   Bredberg, Eva ^b   Andersson, Tommy B ^b,c   Böttiger, Ylva ^a   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

4 hydroxycholesterol; CYP3A4; CYP3A5; Rifampicin

Indexed keywords

4BETA HYDROXYCHOLESTEROL; BIOLOGICAL MARKER; CHOLESTEROL DERIVATIVE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; OXYSTEROL; RIFAMPICIN; UNCLASSIFIED DRUG; CHOLEST 5 ENE 3,4 DIOL; CHOLEST-5-ENE-3,4-DIOL; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; ENZYME INHIBITOR;

4BETA HYDROXYCHOLESTEROL BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; DRUG ANTAGONISM; HALF LIFE TIME; MASS FRAGMENTOGRAPHY; METABOLISM; METHODOLOGY;

BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; HYDROXYCHOLESTEROLS; RIFAMPIN;

EID: 58149129621     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03309.x     Document Type: Article

References (17)

1. Eichelbaum M, Burk O. Cyp3a genetics in drug metabolism. Nat Med 2001 7 : 285 7.
2. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans. Evidence for involvement of cytochrome P450 3A4. J Biol Chem 2001 276 : 38685 9.
3. Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Björkhem I, Diczfalusy U. Metabolism of 4β-hydroxycholesterol in humans. J Biol Chem 2002 277 : 31534 40.
4. Marschall H-U, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundström R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005 129 : 476 85.
5. Josephson F, Bertilsson L, Böttiger Y, Flamholc L, Gisslén M, Ormaasen V, Sönnerborg A, Diczfalusy U. CYP3A induction and inhibition by different antoretroviral regimens reflected by changes in plasama 4β-hydroxycholesterol. Eur J Clin Pharmacol 2008 64 : 775 81.
6. Wide K, Larsson H, Bertilsson L, Diczfalusy U. Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of pediatric patients with epilepsy. Br J Clin Pharmacol 2008 65 : 708 15.
7. Larsson H, Böttiger Y, Iuliano L, Diczfalusy U. In vivo interconversion of 7β-hydroxycholesterol and 7-ketocholesterol, potential surrogate markers for oxidative stress. Free Rad Biol Med 2007 43 : 695 701.
8. Kanebratt KP, Diczfalusy U, Bäckström T, Sparve E, Bredberg E, Böttiger Y, Andersson TB, Bertilsson L. Cytochrome P450 induction by rifampicin in healthy subjects: determination by the Karolinska cocktail and the endogenous CYP3A4 marker 4β-hydroxycholesterol. Clin Pharm Ther Advance online publication 23 July 2008. doi:10.1038/clpt. 2008.132.
9. Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: time-dependent changes - autoinduction of carbamazepine epoxidation. J Clin Pharmacol 1986 26 : 459 62.
10. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet 2003 42 : 819 50.
11. Chobanian AV, Burrows BA, Hollander W. Body cholesterol metabolism in man. II. Measurement of the body cholesterol miscible pool and turnover rate. J Clin Invest 1962 41 : 1738 44.
12. Meaney S, Hassan M, Sakinis A, Lütjohann D, von Bergmann K, Wennmalm Å, Diczfalusy U, Björkhem I. Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J Lipid Res 2001 42 : 70 8.
13. Goodman DS, Smith FR, Sepowitz AH, Ramakrishnan R, Dell RB. Prediction of the parameters of whole body cholesterol metabolism in humans. J Lipid Res 1980 21 : 699 713.
14. Ostlund RE Jr. A minimal model for human whole body cholesterol metabolism. Am J Physiol 1993 265 : E513 20.
15. Meaney S, Bodin K, Diczfalusy U, Björkhem I. On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J Lipid Res 2002 43 : 2130 5.
16. Lange Y, Ye J, Strebel F. Movement of 25-hydroxycholesterol from the plasma membrane to the rough endoplasmic reticulum in cultured hepatoma cells. J Lipid Res 1995 36 : 1092 7.
17. Diczfalusy U, Miura J, Roh H-K, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, Kim J-W, Aklillu E, Gustafsson LL, Bertilsson L. The concentration of 4β-hydroxycholesterol in plasma is an endogenous marker of CYP3A4 enzyme activity - relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008 18 : 201 8.